Pharmacokinetics in children

The SmPC does not list pharmacokinetic data in children.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

In rare cases, states of confusion and/or visual hallucinations may occur. In such cases the patch should be removed immediately. If the symptoms persist despite this, appropriate therapeutic appropriate therapeutic measures should be taken, e.g. slow i.v. (intravenous) administration of 1-4 mg (0.5 mg in children) physostigmine which can be repeated if necessary.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

• ALIMENTARY TRACT AND METABOLISM
• ANTIEMETICS AND ANTINAUSEANTS

ANTIEMETICS AND ANTINAUSEANTS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

References

1. Baxter Medical AB, SmPC Scopoderm (MT-nr.: 7000) 10-01-2014, https://www.legemiddelsok.no
2. Baxter Medical AB, SmPC Scopoderm (MT-nr.: 7000) 28.04.2025, https://www.legemiddelsok.no

Changes

Therapeutic Drug Monitoring

Overdose